Deals

OIS Index Outperforms

OIS Index Outperforms

By Michael Lachman | December 4, 2019

The OIS Index of ophthalmic stocks gained 5.4% in November, following a similar 5.2% gain in October. The index outperformed medical device stocks (+4.3%) and…

Read More
Bausch, Clearside See Gains Post-Deal

Bausch, Clearside See Gains Post-Deal

By Steve Lenier | November 20, 2019

When it comes to the stock market, Bausch Health’s has been rising steadily, up 4.1% in the past month, and on November 13 hit a…

Read More
Private Financing Trends: Ophthalmology Ranks Tenth

Private Financing Trends: Ophthalmology Ranks Tenth

By Steve Lenier | November 7, 2019

SAN FRANCISCO, Calif. — Almost $25 billion in venture funds have been raised in just the United States alone over the past 2.5 years to…

Read More
OIS Index Nov. 2019

OIS Index on Positive Upswing

By Michael Lachman | November 6, 2019

The OIS Index of ophthalmic stocks gained 5.2% in October, posting its first month of positive performance since June. The index lagged the biotech sector…

Read More
Opthea’s Star Brightens for Stakeholders

Opthea’s Star Brightens for Stakeholders

By Keith Croes | October 30, 2019

It’s been a good year for Opthea Ltd., a biotechnology company based in Melbourne, Australia. It’s listed on the Australian Securities Exchange (ASX), trading as…

Read More
At OIS: Rarities and Thought Provokers

At OIS: Rarities and Thought Provokers

By OIS Contributor | October 18, 2019

OIS Contributors An eye drop with the potential to fix, albeit temporarily, presbyopia. An artificial endothelial cornea, ready for trial. A neurostimulation device for dry…

Read More
OIS Index Deep in Bear Territory in Q3

OIS Index Deep in Bear Territory in Q3

By Michael Lachman | October 2, 2019

The OIS Index of ophthalmic stocks posted a miserable Q3 performance, led by the biopharmaceutical stocks in the index. The OIS Index (-12.0%) underperformed the…

Read More
Retina Treatment Beyond Protocol

Retina Treatment Beyond Protocol

By Keith Croes | October 2, 2019

CHICAGO — Optimal treatment of retinal diseases hinges on better understanding in three primary areas, said an expert panel at OIS@ASRS 2019: the disease mechanisms…

Read More
What Has 50 Companies, Four Breakout Sessions, Winning Pitch Winners, and a Keynote Conversation? OIS@AAO 2019

What Has 50 Companies, Four Breakout Sessions, Winning Pitch Winners, and a Keynote Conversation? OIS@AAO 2019

By Steve Lenier | September 25, 2019

SAN FRANCISCO — Winners of a “Shark Tank” style challenge in cataract/refractive and retina and specialty showcase sessions targeting four themes, including gene and cell…

Read More
5 Factors for Evaluating Investments in the Retina Space

5 Factors for Evaluating Investments in the Retina Space

By Steve Lenier | September 11, 2019

As noted in a previous installment, innovators in the retina space sometimes utilize ex-US partnerships for financing the expensive process of taking drugs and devices…

Read More
As Retina Innovators Look Outside US for Funding, Here’s What to Watch Out For

As Retina Innovators Look Outside US for Funding, Here’s What to Watch Out For

By Steve Lenier | September 4, 2019

CHICAGO – As innovation in the retina space has grown over the past quarter century, so has the need for capital to finance those activities.…

Read More
Glaukos' Bid for Avedro: What's Next

A Closer Look at Glaukos’ Bid for Avedro

By Keith Croes | August 14, 2019

Early market reaction to Glaukos Corp.’s all-stock acquisition of Avedro Inc. was mixed; a decrease in stock price for Glaukos and an increase for Avedro.…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.